Solvonis Therapeutics plc (LON:SVNS)

Solvonis Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	May 31, 2021
Revenue	-	-	0.59	0.54	0.38	0.52
Revenue Growth (YoY)	-	-	8.30%	44.37%	-27.80%	57.58%
Cost of Revenue	-	-	0.45	0.24	0.2	0.03
Gross Profit	-	-	0.14	0.3	0.17	0.49
Selling, General & Admin	2.58	1.51	2.36	2.91	1.71	1.03
Other Operating Expenses	-	-	-	-0.02	-0	-0.1
Operating Expenses	2.58	1.51	2.54	3	1.79	0.93
Operating Income	-2.58	-1.51	-2.4	-2.7	-1.62	-0.44
Interest Expense	-0	-0.06	-0	-0	-0.01	-
Other Non Operating Income (Expenses)	-	-	-	-	-	-0.01
EBT Excluding Unusual Items	-2.59	-1.57	-2.4	-2.71	-1.64	-0.45
Gain (Loss) on Sale of Assets	-0.01	0.13	-	-	-	-
Asset Writedown	-	-	-0.72	-	-	-
Pretax Income	-2.6	-1.45	-3.12	-2.71	-1.64	-0.45
Earnings From Continuing Operations	-2.6	-1.45	-3.12	-2.71	-1.64	-0.45
Earnings From Discontinued Operations	0.01	-0.14	-	-	-	-
Net Income	-2.59	-1.59	-3.12	-2.71	-1.64	-0.45
Net Income to Common	-2.59	-1.59	-3.12	-2.71	-1.64	-0.45
Shares Outstanding (Basic)	2,600	1,157	104	104	70	69
Shares Outstanding (Diluted)	2,600	1,157	104	104	70	69
Shares Change (YoY)	2177.31%	1011.63%	0.45%	47.98%	1.45%	1.47%
EPS (Basic)	-0.00	-0.00	-0.03	-0.03	-0.02	-0.01
EPS (Diluted)	-0.00	-0.00	-0.03	-0.03	-0.02	-0.01
Free Cash Flow	-1.72	-1.13	-1.45	-3.08	-0.44	-0.18
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.03	-0.01	-0.00
Gross Margin	-	-	24.02%	55.35%	46.12%	94.23%
Operating Margin	-	-	-408.18%	-498.34%	-431.96%	-85.39%
Profit Margin	-	-	-531.52%	-499.08%	-435.62%	-86.73%
Free Cash Flow Margin	-	-	-247.70%	-567.90%	-116.44%	-34.81%
EBITDA	-	-1.34	-2.23	-2.59	-1.54	-0.36
EBITDA Margin	-	-	-	-	-	-69.62%
D&A For EBITDA	-	0.17	0.17	0.11	0.08	0.08
EBIT	-2.58	-1.51	-2.4	-2.7	-1.62	-0.44
EBIT Margin	-	-	-	-	-	-85.39%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.